These 4 work in 3 different ways, so they are not straight substitutes for each other.
They are aimed at different things: BPC-157 at build & hold muscle; TB-500 at grow & hold muscle; Coremend blend at healing & recovery; KPV at inflammation.
| Comparison | BPC-157 Body Protection Compound 157 · Pentadecapeptide BPC 157 | TB-500 / Thymosin Beta-4 TB4 · thymosin beta 4 | Coremend blend (TB-500 / BPC-157 / KPV) Coremend · TB-500 + BPC-157 + KPV | KPV lysine-proline-valine |
|---|---|---|---|---|
| How it works | How it works BPC-157 is a 15-amino-acid chain based on a protective protein found in stomach acid. It is one of the most widely used peptides here and one of the least studied in humans. | How it works TB-500 is a fragment of thymosin beta-4, a protein your body already uses when tissue needs repairing. Its main job is helping cells move. | How it works Coremend sits between two blends this library already covers, and the interesting part is the ratio rather than the ingredients. | How it works KPV is three amino acids long: the tail end of alpha-MSH with the part that causes tanning removed. It keeps the anti-inflammatory action and loses the pigmentation. |
| What it is | A popular healing peptide for injuries, gut, and joint or tendon pain. | A recovery peptide for healing muscle and tendon, often paired with BPC-157. | A named healing triple that is the Wolverine blend with KPV added. | A tiny anti-inflammatory peptide for gut and skin, with no tanning effect. |
| Status | Research only | Research only | Research only | Research only |
| Typical dose | 0.25–0.5 mg per dose | 2–5 mg per week | 0.25–0.5 mg per day | 0.2–0.5 mg per day |
| How often | 1-2x daily | 1-2x per week | Varies | Daily, 4-8 wk courses |
| Stays active | About 8 to 30 minutes in rats | Not established | None of the three has a published human figure | Nothing published |
| Dose comes from | Community practice | Community practice | Community practice | Community practice |
| Cycled? | Commonly run in 4 to 8 week blocks around an injury, then stopped Community practice | Commonly a loading period of 4 to 6 weeks, then less often, then stopped Community practice | Not established for the blend No established range | Taken in daily, 4-8 wk courses Community practice |
| What it does | ||||
| Drug class | Repair peptide | Repair peptide | TB-500 + BPC-157 + KPV blend | Anti-inflammatory tripeptide |
| Used for | A popular healing peptide people use to bounce back faster from injuries, gut problems, and joint or tendon pain. It is a favorite for recovery. | A recovery peptide used to heal muscles, tendons, and other injuries faster and move more freely. It is often paired with BPC-157. | An injected three-peptide blend sold for tissue repair, recovery and inflammation. | A tiny anti-inflammatory peptide people use to calm inflammation in the gut and skin, popular for IBD, colitis, and skin flare-ups. |
| Receptors hit | — | — | — | — |
| Numbers | ||||
| Full dose line | 0.25 up to 0.5 mg per dose (start low, increase slowly) | 2 up to 5 mg per week (start low, increase slowly) | Research only | 0.2 up to 0.5 mg per day (start low, increase slowly) |
| Why that cycle | The block length is a community convention tied to how long a soft-tissue injury takes to settle. No human study has tested a duration, and none has looked at what long-term use does, so there is no evidence either that a break is needed or that it is safe to skip one. | The loading-then-maintenance shape comes from community practice. No human study has tested a duration or a break. | No schedule has been studied for this combination. The components have different clearance times and different conventional frequencies, so a single shared schedule is a convenience of the vial rather than a finding. | Course dosing is how this one is normally used. Where the course length comes from is the thing to check: for most compounds in this pattern it is convention rather than a tested schedule. |
| Weight / effect | Not measured in a trial | Not measured in a trial | Not measured in a trial | Not measured in a trial |
| Chain length | 15 residues | 43 residues | Not disclosed | 3 residues |
| Common vial | 5 mg | 10 mg | — | 10 mg |
| Before you start | ||||
| Route | Under the skin, into muscle, or by mouth | Under the skin or into muscle | Under the skin (subcutaneous) | By mouth, under the skin, or on the skin |
| Do not use if | Active cancer, as a precaution given that it promotes new blood-vessel growth Pregnancy Banned in drug-tested sport | Active cancer, as a precaution given the tissue-growth mechanism Pregnancy Banned in drug-tested sport | Pregnancy or breastfeeding Active cancer, as a precaution with anything that promotes tissue or blood-vessel growth Anyone competing in drug-tested sport, because TB-500 is named on the WADA prohibited list Anyone who wants established safety data, because none exists for this combination in humans | No controlled human trials exist, so no contraindications are established Pregnancy |
What separates them
Proof behind the dose. Every dose here comes from community practice. Not one is backed by a published human study, which is worth knowing before you read the numbers as if they were equivalent.
What doesn't differ: None of them has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
BPC-157
- Almost all the evidence so far is from animal studies, not people.
- There is a theoretical cancer concern because it promotes new blood-vessel growth.
- Banned in drug-tested sport.
- Signs of an allergic reaction
- New lumps or masses
TB-500 / Thymosin Beta-4
- It is mostly tested in animals, with limited human data.
- Most products sold are a fragment rather than the full protein.
- Banned in drug-tested sport.
- Signs of an allergic reaction
- New lumps or masses
Coremend blend (TB-500 / BPC-157 / KPV)
- No trial has tested this combination in people.
- The uneven ratio pushes TB-500 above its usual weekly amount if the blend is dosed daily.
- Signs of an allergic reaction, including spreading hives, facial or throat swelling, or trouble breathing
- Redness, heat, or pus at the injection site, which can signal infection
KPV
- There are no human trials yet, so safety is inferred from animal work.
- Unlike some similar peptides, it does not cause tanning.
- Signs of an allergic reaction
- Anything unusual, given the absence of human data
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.